Type 2 diabetes linked to nearly 4x higher cirrhosis risk in under-50s

Fatty liver disease has long been treated as a problem of aging—something that accumulates over decades, something you worry about later. A new study of nearly 2,400 adults with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease, or MASLD, suggests that assumption may be dangerously wrong, at least for people with type 2 diabetes.

Among the 234 participants in the study who had developed cirrhosis, roughly one in four had done so before turning 50. That alone is striking enough to reframe how clinicians think about liver risk in younger patients. But the deeper finding is more specific: when researchers accounted for age, weight, and other metabolic factors, people under 50 with type 2 diabetes had nearly four times the odds of cirrhosis compared to their peers without diabetes. The association was strong enough to survive statistical adjustment—meaning it was not simply a byproduct of obesity or other confounding variables.

Genetic inheritance appears to amplify that risk considerably. The study incorporated genetic variants in three genes previously linked to liver disease: PNPLA3, TM6SF2, and HSD17B13. People carrying more of these variants had more than double the odds of early cirrhosis. This suggests that some younger adults inherit a susceptibility to liver disease that, when combined with the metabolic stress of type 2 diabetes, can accelerate the progression from fatty infiltration through inflammation and scarring all the way to cirrhosis—a process that might otherwise take decades.

It is important to note what the study does not show. The research was observational, meaning it identified an association but cannot prove that type 2 diabetes directly caused the cirrhosis. The participants were also selected because they had already undergone liver biopsy, typically because a clinician suspected liver disease—they do not represent the full population of people living with type 2 diabetes in routine primary care. The findings are suggestive, not definitive.

Yet the practical implication is clear and already reflected in European clinical guidance: younger patients with type 2 diabetes, particularly those with obesity or additional metabolic risk factors, warrant screening for significant liver fibrosis. The danger lies in reassurance based on age alone. A person under 50 with type 2 diabetes can harbor substantial scarring in the liver without obvious symptoms and without the kind of dramatically elevated liver enzymes that might trigger alarm. The disease can be silent.

MASLD itself exists on a spectrum. It begins as simple fat accumulation in liver cells, a condition that can be reversible. But in some people it progresses to inflammation, then to fibrosis—the buildup of scar tissue that stiffens the organ and impairs its function. Cirrhosis is the endpoint, the point at which the liver has been so damaged that it can no longer perform its essential work. The new research suggests that this progression, once thought to be the province of older adults, can happen much faster in younger people carrying both metabolic and genetic risk.

The takeaway for clinicians is a shift in how they approach liver assessment in their younger diabetic patients. Age should not be used as a reason to skip screening or to dismiss a patient's liver risk. Someone with type 2 diabetes in their 40s or even 30s may need the same vigilance as someone older. The study does not answer every question—it does not tell us how common early cirrhosis truly is across the broader population of younger people with diabetes, nor does it establish the best screening strategy or intervention. But it does challenge a comfortable assumption, and in medicine, that is often where change begins.